Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfad051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Sarah W Y Lok und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Hauptthemen laut MEDLINE: Acute Kidney Injury, Renal Insufficiency, Chronic, Reperfusion Injury, Vascular System Injuries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Health and Medical Research Fund, Research Grants Council of Hong Kong, Hong Kong Society of Nephrology.
Abstract (Originalsprache)
Background
Thromboembolic events are prevalent in chronic kidney disease (CKD) patients due to increased thrombin generation leading to a hypercoagulable state. We previously demonstrated that inhibition of protease-activated receptor-1 (PAR-1) by vorapaxar reduces kidney fibrosis.
Methods
We used an animal model of unilateral ischemia–reperfusion injury-induced CKD to explore the tubulovascular crosstalk mechanisms of PAR-1 in acute kidney injury (AKI)-to-CKD transition.
Results
During the early phase of AKI, PAR-1-deficient mice exhibited reduced kidney inflammation, vascular injury, and preserved endothelial integrity and capillary permeability. During the transition phase to CKD, PAR-1 deficiency preserved kidney function and diminished tubulointerstitial fibrosis via downregulated transforming growth factor-β/Smad signaling. Maladaptive repair in the microvasculature after AKI further exacerbated focal hypoxia with capillary rarefaction, which was rescued by stabilization of hypoxia-inducible factor and increased tubular vascular endothelial growth factor A in PAR-1-deficient mice. Chronic inflammation was also prevented with reduced kidney infiltration by both M1- and M2-polarized macrophages. In thrombin-induced human dermal microvascular endothelial cells (HDMECs), PAR-1 mediated vascular injury through activation of NF-κB and ERK MAPK pathways. Gene silencing of PAR-1 exerted microvascular protection via a tubulovascular crosstalk mechanism during hypoxia in HDMECs. Finally, pharmacologic blockade of PAR-1 with vorapaxar improved kidney morphology, promoted vascular regenerative capacity, and reduced inflammation and fibrosis depending on the time of initiation.
Conclusions
Our findings elucidate a detrimental role of PAR-1 in vascular dysfunction and profibrotic responses upon tissue injury during AKI-to-CKD transition and provide an attractive therapeutic strategy for post-injury repair in AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
ORCID-Profile: Sydney C W Tang
Förderung
- Health and Medical Research Fund
- Research Grants Council of Hong Kong
- Hong Kong Society of Nephrology
- Hong Kong Kidney Foundation
Zitieren
APA
Lok, S. W. Y., Yiu, W. H., Zou, Y., Xue, R., Li, H., Ma, J., Chen, J., Chan, L. Y. Y., Lai, K. N., & Tang, S. C. W. (2023). Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad051
Vancouver
Lok SWY, Yiu WH, Zou Y, Xue R, Li H, Ma J, et al. Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfad051
BibTeX
@article{Lok2023,
author = {Lok, Sarah W Y and Yiu, Wai Han and Zou, Yixin and Xue, Rui and Li, Hongyu and Ma, Jingyuan and Chen, Jiaoyi and Chan, Loretta Y Y and Lai, Kar Neng and Tang, Sydney C W},
title = {Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfad051}
}
EUVIMED